[1] Smith L, McCourt O, Henrich M, et al. Multiple myeloma and physical activity: a scoping review[J]. BMJ Open, 2015, 5(11): e009576. DOI: 10.1136/bmjopen-2015-009576.
[2] Rllig C, Knop S, Bornhuser M. Multiple myeloma[J]. Lancet, 2015, 385(9983): 2197-2208. DOI: 10.1016/S01406736(14)60493-1.
[3] Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma[J]. Am Soc Clin Oncol Educ Book, 2014: 199-203. DOI: 10.14694/EdBook_AM.2014.34.199.
[4] Neri P, Bahlis NJ, Lonial S. New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma[J]. Clin Cancer Res, 2016, 22(24): 5959-5965. DOI: 10.1158/1078-0432.CCR-16-0184.
[5] ZelleRieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site[J]. J Hematol Oncol, 2016, 9(1): 116. DOI: 10.1186/s13045-016-0345-3.
[6] Zou X, Liang J, Sun J, et al. Allicin sensitizes hepatocellular cancer cells to antitumor activity of 5fluorouracil through ROSmediated mitochondrial pathway[J]. J Pharmacol Sci, 2016, 131(4): 233-240. DOI: 10.1016/j.jphs.2016.04.017.
[7] Laubach JP, SanMiguel JF, Hungria V, et al. Deacetylase inhibitors: an advance in myeloma therapy?[J]. Expert Rev Hematol, 2017, 10(3): 229-237. DOI: 10.1080/17474086.2017.1280388.
[8] Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma[J]. Nat Rev Clin Oncol, 2015, 12(1): 42-54. DOI: 10.1038/nrclinonc.2014.200.
[9] Laubach JP, Paba Prada CE, Richardson PG, et al. Daratumumab, elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma[J]. Clin Pharmacol Ther, 2017, 101(1): 81-88. DOI: 10.1002/cpt.550.
[10] Sasaki M. Current treatment of refractory and relapsed multiple myeloma[J]. Rinsho Ketsueki, 2016, 57(10): 2084-2095. DOI: 10.11406/rinketsu.57.2084.
[11] Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon[J]. Bone Marrow Transplant, 2013, 48(1): 10-18. DOI: 10.1038/bmt.2012.26.
[12] Luo R, Fang D, Hang H, et al. The mechanism in gastric cancer chemoprevention by allicin[J]. Anticancer Agents Med Chem, 2016, 16(7): 802-809.
[13] Bodinghaus J, Albrecht F, Gruhlke MC, et al. Allicin: chemistry and biological properties[J]. Molecules, 2014, 19(8): 1259112618. DOI: 10.3390/molecules190812591.
[14] 贾丽. 大蒜素抑制人子宫内膜癌Ishikawa细胞生长的实验研究[J]. 医学研究杂志, 2017, 46(2): 127-130. DOI: 10.11969/j.issn.1673-548X.2017.02.033.
[15] 佘玉清, 陈昱倩, 颜延凤, 等. 不同浓度苦参碱、大蒜素对人胃癌细胞株MKN45杀伤作用的实验研究[J]. 江苏中医药, 2014, 46(11): 82-83.
[16] 刘扬清, 高勇, 万一元, 等. 大蒜素对结肠癌LoVo细胞增殖的影响[J]. 临床肿瘤学杂志, 2009, 14(2): 139-143.
[17] 朱少伟, 邵淑丽, 张蕾, 等. 大蒜素诱导人胃癌SGC-7901细胞凋亡[J]. 中国细胞生物学学报, 2017, 39(1): 6-12. DOI: 10.11844/cjcb.2017.01.0219.
[18] 邵淑丽, 刘锐, 隋文静, 等. 大蒜素诱导结肠癌HT-29细胞凋亡[J]. 基因组学与应用生物学, 2015, 34(2): 227-233. DOI: 10.13417/j.gab.034.000227.
[19] Xu L, Yu J, Zhai D, et al. Role of JNK activation and mitochon drial bax translocation in allicininduced apoptosis in human ovarian cancer SKOV3 cells[J]. Evid Based Complement Alternat Med, 2014, 2014: 378684. DOI: 10.1155/2014/378684.
[20] 张飞凤, 谭布珍. 大蒜素诱导卵巢癌耐顺铂细胞株SKOV3/DDP凋亡机制的初步探讨[J]. 时珍国医国药, 2014, 25(8): 2029-2030. DOI: 10.3969/j.issn.1008-0805.2014.08.094.
[21] 张敏, 奚杰, 孙大伟, 等. 大蒜素对宫颈癌细胞生长的影响及作用机制[J]. 中国实用妇科与产科杂志, 2011, 27(1): 39-41.
[22] Fichtl J, Treska V, Lysak D, et al. Predictive value of growth factors and interleukins for future liver remnant volume and colorectal liver metastasis volume growth following portal vein embolization and autologous stem cell application[J]. Anticancer Res, 2016, 36(4): 1901-1907.
[23] Wang M, Wu D, Liu P, et al. Silence of MCL1 upstream signaling by shRNA abrogates multiple myeloma growth[J]. Exp Hematol Oncol, 2014, 3(1): 27. DOI: 10.1186/21623619-3-27. |